$8.57 BillionThe market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.
$120.76 - $216.90The lowest and highst price in the last 52 weeks.
18.19xThe price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.
$0.00 (0.0%)Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).
|Market Cap||$8.57 Billion|
|Enterprise Value||$7.4 Billion|
|Dividend Yield||$0.00 (0.0%)|
|1 Year Return||+60.4%|
|Outstanding Shares||44.9 Million|
|Avg 30 Day Volume||362 Thousand|
|Earnings per Share||$10.26|
|Price to Sales Ratio||5.46|
|Price to Book Ratio||2.36|
|Revenue to Enterprise Value||4.65|
|EBIT to Enterprise Value||16.67|
|Total Debt to Enterprise Value||0.11|
|Debt to Equity||0.22|
|Gross Profit||$1.47 Billion|
|Net Income||$471 Million|
|Quarterly Earnings Growth (YoY)||+61.2%|
|Return on Equity||12.94%|
|Return on Assets||9.72%|
|Return on Invested Capital||9.79%|
3,460 shares sold (2 transactions)
CEO: Martine Rothblatt
Industry: Pharmaceutical Preparation Manufacturing
United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power of our brands, our entrepreneurial culture and our bioinformatics leadership. We also believe that our determination to be responsible citizens - having a positive impact on patients, the environment and society - will sustain our success in the long term. Through our wholly-owned subsidiary, Lung Biotechnology PBC, we are focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company.
United Therapeutics Co. (NASDAQ:UTHR)s share price was up 3.7% during trading on Wednesday . The stock traded as high as $193.24 and last traded at $193.24. Approximately 607 shares traded hands du...Dakota Financial News, 3 days ago
Legg Mason Asset Management Japan Co. Ltd. reduced its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 8.2% in the 2nd quarter, according to its most recent 13F filing with the Secur...Transcript Daily, 4 days ago
United Therapeutics UTHR announced that the FDA has issued a complete response letter to its new drug application (“NDA”) for its drug device combination therapy, Tyvaso Dry Powder Inhaler or Tyvas...FXNews24, 5 days ago